Finance

Beta
Lists
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$247.53
+2.21%
(+5.35) 1D
$248.00
+0.19% (+0.47)
After hours
Closed: Jul 17, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JAZZ...
Open
$241.61
High
$249.50
Low
$238.08
Mkt. cap
15.55B
Avg. vol.
862.25K
Volume
503.56K
P/E ratio
2,327.72
52-wk high
$250.49
52-wk low
$105.00
EPS
$0.11
Beta
0.32
Shares outstanding
62.82M
No. of employees
3K
Open
$241.61
High
$249.50
Low
$238.08
Mkt. cap
15.55B
Avg. vol.
862.25K
Volume
503.56K
P/E ratio
2,327.72
52-wk high
$250.49
52-wk low
$105.00
EPS
$0.11
Beta
0.32
Shares outstanding
62.82M
No. of employees
3K
News stories
From sources across the web
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com
Analyst ratings
Based on 18 analysts giving stock ratings to JAZZ in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for JAZZ in the last 3 months.
Highest
Current $247.53
$307.00 (+24.03%)
Average
$264.50 (+6.86%)
Lowest
$229.00 (-7.49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gary Nachman
Canaccord Genuity
Buy
Initiated
$290.00
+17.2%
07/17/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$285.00
+15.1%
07/14/2026
Etzer Darout
Barclays
Buy
Maintained
$260.00
+5%
07/14/2026
Unknown Analyst
Jefferies
Buy
Maintained
$282.00
+13.9%
07/13/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
07/10/2026
David Hoang
Deutsche Bank
Buy
Maintained
$270.00
+9.1%
07/09/2026
Gregory Renza
Truist Financial
Buy
Maintained
$254.00
+2.6%
07/07/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$258.00
+4.2%
07/07/2026
Ashwani Verma
UBS
Buy
Maintained
$307.00
+24%
07/01/2026
Ami Fadia
Needham
Buy
Maintained
$255.00
+3%
06/29/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$301.00
+21.6%
06/16/2026
Joseph Thome
TD Cowen
Buy
Maintained
$275.00
+11.1%
06/12/2026
Joon Lee
Truist Financial
Buy
Initiated
$256.00
+3.4%
06/09/2026
Jeffrey Walch
Bernstein
Hold
Reiterated
$229.00
-7.5%
06/08/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
-
-
06/02/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$265.00
+7.1%
05/20/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$252.00
+1.8%
05/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
$239.00
-3.4%
05/06/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$230.00
-7.1%
05/06/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$245.00
-1%
05/05/2026
Unknown Analyst
Raymond James
Buy
Maintained
$239.00
-3.4%
05/06/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$6.34 / $4.63
+36.79%beat
Revenue / Est. (USD)
1.07B / 979.34M
+9.14%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.05B
1.13B
1.20B
1.07B
Cost of goods sold
116.27M
128.88M
112.92M
96.60M
Cost of revenue
116.27M
128.88M
112.92M
96.60M
Research and development expenses
189.97M
198.20M
172.66M
196.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
358.40M
379.15M
418.46M
352.70M
Operating expense
710.47M
745.72M
760.86M
721.00M
Total operating expenses
826.74M
874.60M
873.79M
817.60M
Operating income
218.97M
251.51M
324.14M
251.30M
Other non operating income
-
-
-
122.80M
EBT including unusual items
-735.64M
8.99M
208.41M
299.20M
EBT excluding unusual items
169.72M
202.99M
278.02M
336.70M
Income tax expense
-17.17M
-242.42M
4.96M
6.10M
Effective tax rate
2.33%
-2,697.20%
2.38%
2.04%
Other operating expenses
-
-
-
-
Net income
-718.47M
251.41M
203.45M
293.10M
Net profit margin
-68.71%
22.33%
16.98%
27.42%
Earnings per share
-8.25
8.13
6.64
6.34
Interest and investment income
19.10M
18.60M
20.50M
23.40M
Interest expense
-66.46M
-67.18M
-65.91M
-63.30M
Net interest expenses
-47.36M
-48.58M
-45.41M
-39.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
392.98M
429.76M
503.31M
432.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer